1 T cells. Ligating one such receptor, complement receptor 2 (CR2), has also been described to induce co-stimulatory molecule expression. If correct, this may have serious consequences for ensuring the specificity of the resultant B cell response. We have therefore investigated the effects of ligating both the BCR and CR2 independently of each other, as well as with reagents to cross-link the two receptors, in order to clarify these findings. In contrast to the effects seen upon BCR ligation, we find no evidence for co-stimulatory molecule up-regulation following CR2 ligation. As antigen presentation in the absence of co-stimulation may lead to the induction of tolerogenic or regulatory signals being delivered to T cell populations, these findings imply that the role of CR2 in B cellmediated antigen presentation is different from that of the BCR.
Introduction
Antibody responses are initiated by individual B cell clones binding and internalizing antigens via their surface Ig B cell receptors (BCR) (1) (2) (3) (4) . Once delivered into the B cell endocytic environment, the BCR-antigen complex becomes a substrate for proteolysis (5, 6) , [reviewed in (7) ] in a process similar to that seen in other antigen-presenting cells (APC). This culminates in the generation of small peptide fragments that associate with MHC class II molecules (6, 8, 9) . These peptide-MHC (pMHC) complexes are subsequently exported to the cell surface (10, 11) for recognition by CD4 + T cells. Importantly, as well as the pMHC complex, activation of CD4 + T cells also requires additional signals from APC, termed co-stimulation. Indeed, if these secondary signals are absent, T cell anergy/death, rather than activation, may result (12) .
Many studies have shown that APC express a number of surface co-stimulatory molecules that are members of the B7 molecular family. These provide this second signal by interacting with the constitutively expressed T cell co-stimulation receptor, CD28 [reviewed in (13) ]. Accordingly, B cell activation through the BCR has been shown to up-regulate surface expression of both B7-1 (CD80) and B7-2 (CD86) (14, 15) .
In addition to these two initiating signals (pMHC and costimulation), it is also believed that the type of APC affects the developing T cell response. In particular, antigen presentation by B cells has been demonstrated to bias the response toward the T h 2 phenotype via the ligation of CD40 on the B cell surface with the inducible CD40L on the T cell (15) (16) (17) , leading to increased T cell IL-4 production. Thus, by a combination of BCR-mediated antigen presentation, induced co-stimulation and CD40 expression, B cells can be pivotal in inducing T h 2 polarization, eliciting help for their subsequent proliferation and differentiation into antibody-secreting plasma cells.
Although the molecular interactions of B and T cell collaborations following BCR-mediated antigen uptake is becoming clear, substantial evidence exists that B cells can also present antigens that have been captured and internalized by receptors other than the BCR (18) (19) (20) (21) (22) (23) (24) (25) . In particular, it has been shown in vivo that targeting antigen to the complement receptor 2 (CR2) complex dramatically increases the resulting antibody response (26, 27) . This effect has also been studied in vitro, and has been shown to partly be due to the ability of complement 'tagged' antigens to cross-link CR2 to the BCR on the surface of B cells (25, (28) (29) (30) (31) (32) . As well as having a role as a BCR co-receptor, CR2 has also been shown to be capable of mediating antigen presentation independently of the BCR (18, 25, 33, 34) . These findings have prompted investigations into the consequences of CR2-mediated antigen presentation in B cells, in particular with respect to the effect on subsequent CD4 + T cell activation. The interpretation of these experiments will prove crucial in understanding any role of CR2-mediated antigen presentation by B cells. However, the conclusions drawn from these studies are inconsistent. Initial experiments with human (h) B cells demonstrated that, while hCR2-mediated antigen presentation led to T cell stimulation, CD80 expression was not induced unless cross-linking to FcRcII was included (33) . A later study showed that hCR2-mediated antigen presentation did not lead to the delivery of T cell help and the B cells failed to secrete Ig (35) . In contrast, Kozono et al. (36) demonstrated that mouse (m) splenic B cells up-regulated the expression of both CD80 and CD86 following mCR2 ligation. More recently, additional studies (37, 38) have demonstrated that cross-linking hCR2 to the BCR, in the presence of IL-4, enhances up-regulation of both CD80 and CD86 expression compared with BCR ligation alone. However, in the absence of IL-4, this hCR2-mediated enhancement was only witnessed when hCR2/BCR ligation was performed at very low ligand doses.
In this study we have re-examined levels of co-stimulatory molecules expressed on mouse splenic B cells following ligation of either mCR2 or BCR independently, or after crosslinking the two antigen receptors. We clearly demonstrate that, unlike BCR ligation, independent ligation of mCR2 does not lead to any changes in CD80, CD86 or B7h expression levels, either in the presence or absence of IL-4. Furthermore, we show that cross-linking mCR2 to the BCR does not augment levels of CD80, CD86 or B7h above levels induced upon BCR ligation alone. This is also seen when BCR ligation is performed at levels below receptor saturation. The implications of these findings for CD4 + T cell activation, in the context of previous studies, are discussed.
Methods

B cell isolation
Using CD43-negative depletion, splenic B cells were isolated from male C57BL/6, BALB/c or mutant mice lacking expression of FcRcII (39) I-labeled with Bolton Hunter reagent (Amersham Biosciences) as described (44) . To assess the kinetics of its binding,~2 3 10 6 CD43-negative B cells were incubated with graded amounts of labeled antibody at 4°C for 1 h in RPMI-1640 supplemented with 2% FCS (First Link, Birmingham, UK). After extensive washing, cell-associated label was measured using a Packard MINAXI gamma counter. Specificity of binding was checked by the inclusion of samples containing 100-fold excess non-labeled 7E9, typically quenching cell-associated label by 95%.
B cell treatments
mAbs to either mBCR or mCR2 were used as a means of receptor ligation. To target the BCR, biotin-conjugated F(ab9) 2 fragment, goat anti-mouse IgM (Jackson Immunoresearch Laboratories, West Grove, PA, USA) antibodies were used at a concentration of 3.4 lg ml ÿ1 , unless stated otherwise. mCR2 was targeted with either 2 lg ml ÿ1 of the biotinylated mAbs 7E9 or 7G6 (both of which also bind the closely related molecule, CR1) (43) or with a recombinant antigen consisting of three tandem copies of the natural ligand for mCR2 (mC3d) fused to the C-fragment of the bacterial antigen tetanus toxin (TTCF) [(C3d) 3 -TTCF] (25, 45) . To target FcRcII, biotinyated anti-FcRcII/III/mAb 2.4G2 (46) was used (2 lg ml ÿ1 ). To simulate extensive cross-linking of the individual receptors, 5 lg ml ÿ1 streptavidin (Southern Biotechnology Associates, Birmingham, AL, USA) was also added. To cross-link the various antigen receptors (CR2 to BCR, CR2 to FcRcII) biotinylated anti-CR2, -BCR or -FcRc mAbs were added simultaneously in the appropriate combinations followed by 5 lg ml ÿ1 streptavidin. Cells were cultured at 2 3 10 6 ml ÿ1 in either 24-or 48-well plates (Corning B.V. Life Sciences, Schiphol-Rijk, The Netherlands) at 37°C, in an atmosphere of 5% CO 2 , in RPMI-1640 supplemented with 10% FCS, 100 lg ml ÿ1 kanamycin, 2 mM glutamine, 1 mM sodium pyruvate, non-essential amino acids (all Invitrogen Ltd, Paisley, UK) and 50 lM b-mercaptoethanol (Sigma, Poole, UK) (complete RPMI). Where indicated, media were supplemented with 10 ng ml ÿ1 mIL-4.
Proliferation assays
To measure antibody-induced proliferation,~1.5 3 10 5 cells were incubated, in duplicate, in 96-well plates with the various antibody treatments (at concentrations described above) either in the presence or in the absence of mIL-4 for 65 h with 18.5 kBq [ 
FACS analysis
Cells were incubated with directly labeled antibodies for 30 min at 4°C in PBS + 2% FCS before thorough washing. A total of 10 000 events were collected on a Becton Dickinson FACSCalibur and analyzed using FlowJo 4.6.2 (Tree Star Inc., Ashland, OR, USA). FcRcII binding of all antibodies was controlled for using the blocking anti-FcRcII mAb 2.4G2 (BD Biosciences Pharmingen).
Results
Isolation, analysis and activation of mouse B cells
In order to assess the consequences of mCR2-mediated antigen presentation by B cells, with respect to their ability to stimulate T cells, we decided to clarify the levels of costimulatory molecules CD80 and CD86 on mouse splenic B cells following mCR2 ligation. To ensure that the levels of costimulatory molecules were not affected by the purification procedure itself, we isolated splenic B cells by negative selection using CD43 magnetic beads. CD43 is a transmembrane molecule expressed by a number of lymphoid cell types, but importantly, is absent on the majority of B cells found in the secondary lymphoid organs (termed B-2 B cells) (47) . Approximately 94% of the resulting CD43-negative population were shown to be positive for the B cell markers B220 and CD19 (data not shown). These cells were then subjected to discontinuous Percoll-gradient centrifugation to allow the removal of any activated cells. Figure 1(A) shows the expression profiles of a panel of activation markers on the B cell fractions following centrifugation. It can be seen that the B cells pooled from bands 1, 2 and 3 (termed high density) expressed considerably lower levels of the co-stimulatory markers CD80 and CD86 (as well as the other markers analyzed) than the cells pooled from the other bands. Cells pooled from these lower three bands were therefore used throughout this study.
Anti-mCR2 mAbs do not induce splenic B cell proliferation or up-regulation of co-stimulatory molecule expression
As previous reports had demonstrated that anti-CR2 mAbs failed to induce human B cell proliferation (48) , but did induce up-regulation of both CD80 and CD86 on mouse splenic B cells (36) , we sought to address this apparent discrepancy. We therefore repeated both of these experiments with negatively isolated, naive mouse splenic B cells using the 7E9 antimCR2 mAb. This mAb was confirmed to bind splenic B cells with saturable kinetics (~1-2 lg ml ÿ1 ) (Fig. 1B) , and was calculated to react with~20 000 binding sites/CD43-negative cell, comparable to that seen in other studies (25, 49) . We therefore performed the following experiments using the 7E9 anti-mCR2 mAb to ligate mCR2 on the high-density, CD43-negative B cells. As expected, treatment of B cells with biotinylated anti-BCR mAb (in the presence of cross-linking streptavidin) induced proliferation as measured by [ 3 H]TdR incorporation over a 65-h period. This can be increased by the inclusion of IL-4 in the culture media ( Fig. 2A) . In stark contrast, anti-mCR2 treatment (also in the presence of crosslinking streptavidin), either in the presence or in the absence of IL-4, failed to induce any proliferation above that seen in media controls.
We then examined the levels of CD80 and CD86 expressed by B cells after BCR ligation for a shorter period of 17 h. Figure 2(B) shows, in agreement with a previous report (14) , that, while there is no difference in CD80 expression during this time period, there is an increase in CD86 expression after BCR ligation. This increase in CD86 expression can also be enhanced through the addition of IL-4 (Fig. 2C) . However, when the B cells were treated with the anti-mCR2 mAbs, there was no observed increase in CD80 or CD86 expression in either the absence (Fig. 2B) or presence (Fig. 2C) of IL-4. Thus, mCR2 ligation does not induce co-stimulatory molecules on the surface of mouse splenic B cells after 17 h. In addition, the cross-linking of mCR2 to the BCR failed to induce any further CD86 up-regulation compared with that seen with the anti-BCR treatment only (Fig. 2B and C, bottom panels) .
We next decided to address whether mCR2 ligation may have an effect on CD86 expression after a longer period of Fig. 2 . Anti-mCR2 antibody, 7E9, fails to induce either proliferation or altered expression of the co-stimulatory molecules, CD80 or CD86, on purified splenic B cells. CD43-negative, high-density splenic B cells were incubated with media-alone, biotinylated mAbs directed against BCR (3.4 lg ml ÿ1 ) or mCR2 (7E9; 2 lg ml ÿ1 ) or a combination of both anti-BCR and mCR2 mAbs. Streptavidin (5 lg ml ÿ1 ) was added to the wells containing mAbs to cross-link the ligated receptors. In (A), proliferation was assessed by incorporation of [ time. Figure 3(A) shows that, even after 4 days in the presence of IL-4, mCR2 ligation failed to induce any increase in CD86 expression. As it was apparent that anti-BCR-induced CD86 expression actually declined after 4 days, we decided to explore the possibility that we had yet to find the optimal time period for any anti-mCR2-induced effects. Figure 3(B) shows a time course for CD86 expression levels after various antigen receptor ligation treatments in the presence of IL-4. Anti-BCR ligation induces a rapid up-regulation of CD86, which peaks after 24 h and then declines over the next 3 days. In contrast there is no evidence for CR2-induced CD86 up-regulation over this period.
Recent studies have demonstrated that other members of the B7 family of co-stimulatory molecules also play an important role in APC-mediated T cell stimulation [reviewed in (50) ]. In particular, it has been shown that both B7h (51) and 4-1BBL (52) are expressed by B cells. These co-stimulatory molecules appear to be involved in later T cell activation events by binding the inducible co-stimulator molecules expressed on activated T cells, ICOS and 4-1BB. B7h expression has also been shown to be required for CD4 + T cell polarization (53) and is modified by BCR ligation (54) . We therefore analyzed both B7h and 4-1BBL following various antigen receptor ligation. As can be seen in Fig. 3(C) , Fig. 3 . Kinetic analysis of co-stimulatory molecule expression following BCR and/or mCR2 ligation. CD43-negative, high-density splenic B cells were incubated with media-alone, biotinylated mAbs directed against BCR (3.4 lg ml anti-BCR ligation led to reduced B7h expression [as previously reported (54) ] after 17 h, and did not affect 4-1BBL levels. In contrast, anti-mCR2 treatment had no effect on B7h or 4-1BBL after 17 h (Fig. 3C ) or indeed after 4 days (data not shown).
Previously, Kozono et al. (36) had demonstrated that distinct anti-mCR2 mAbs behave differently in their ability to upregulate CD80 and CD86. 7E9 binds to an epitope other than that involved in natural ligand (C3d) binding to mCR2, whereas another anti-mCR2 mAb 7G6 directly competes for C3d-binding sites (55) . Although Kozono et al. demonstrated that 7E9 was more efficient than 7G6 at inducing CD80 and CD86 expression, we wanted to see if alternative methods of cross-linking mCR2 would induce co-stimulatory molecule expression in our experiments. We therefore repeated these experiments using either this alternate anti-mCR2 mAb (7G6) or a recombinant form of the natural ligand for mCR2 (C3d) 3 fused to the bacterial antigen, the TTCF (45) that is efficiently presented to TTCF-specific T cells in a mCR2-dependent manner (25) . As can be seen in Fig. 4 , anti-mCR2 mAb 7G6, like 7E9, fails to increase expression of CD80 and CD86, both Fig. 4 . Alternate mCR2 ligation also fails to alter levels of co-stimulatory molecules CD80 and CD86 on purified splenic B cells. In (A) and (B), CD43-negative, high-density splenic B cells were incubated with media-alone, biotinylated mAbs directed against BCR (3.4 lg ml ÿ1 ) or mCR2 (7G6; 2 lg ml ÿ1 ) or a combination of both anti-BCR and mCR2 mAbs. Streptavidin (5 lg ml ÿ1 ) was added to the wells containing mAbs to crosslink the ligated receptors. Cells were incubated for 17 h either in the absence (A) or in the presence (B) of 10 ng ml ÿ1 IL-4 before the levels of CD80 (left-hand side histograms) and CD86 (right-hand side histograms) were analyzed. In (C), cells were incubated in media containing IL-4 alone, in media containing IL-4 and biotinylated mAbs directed against mCR2 (7E9; 2 lg ml ÿ1 ) or in media containing IL-4 and (C3d) 3 -TTCF (2 lg ml ÿ1 ). After 17 h the levels of CD80 (left-hand side histograms) and CD86 (right-hand side histograms) were analyzed. in the absence (Fig. 4A) and presence (Fig. 4B) of IL-4, after 17 h or 4 days (data not shown). Likewise, the addition of the natural mCR2 ligand-containing (C3d) 3 -TTCF in the presence of IL-4 also fails to induce any CD80 or CD86 increased expression after incubation for either 17 h (Fig. 4C ) or 4 days (not shown).
Lack of anti-mCR2 mAb-induced CD86 expression is not due to FcR engagement
Although the reagents used in this study appear not to bind to FcRcII expressed by B cells (by blocking studies; not shown), we decided it was important to rule out any possibility that our intact antibodies (used as surrogate receptor ligands) were inducing FcRcII cross-linking. This is of particular importance since many stimuli delivered through the BCR, for example, are negated after cross-linking to FcRcIIB (56) . As it has been documented that mice lacking this FcR do not have any B cell lineage disruption, but do fail to regulate BCR-mediated B cell stimuli, we repeated our antibody treatments using B cells purified in an identical manner from mice lacking FcRcII expression. As these mice are bred on a BALB/c background, we also performed control wild-type (WT) BALB/c B cell isolations in parallel. It can be seen in Fig. 5 (similar to that seen with B cells isolated from C57BL/6 mice; Figs 2-4) that incubation of B cells from either WT or FcRcII null mice (FcRcII KO) with mAbs to mCR2 does not induce the up-regulation of either CD80 or CD86 expression. In contrast, when biotinylated mAbs to both the BCR and mCR2 are added to highdensity B cells [from both types of mice (Figs 4 and 5) ], CD86 expression is seen to increase. Thus, the failure of mCR2 to alter levels of CD80 or CD86 (as well as anti-BCR-mediated CD86 up-regulation) appears independent of FcRcII ligation.
We were also interested to see the effect of cross-linking mCR2 to FcRcII on B cells. Figure 5 (bottom panels) shows the CD80 and CD86 levels on B cells isolated from either WT or FcRcII KO mice after treatment with a combination of antimCR2 and anti-FcRcII mAbs. It can be seen that, like treatment of cells with just anti-mCR2 mAbs, cross-linking mCR2 to the FcRcII also fails to alter CD80 and CD86 levels. mCR2 cross-linked to the BCR at low ligand occupancy fails to up-regulate CD86 co-stimulatory activity
In previous studies it has been reported that, in the absence of IL-4, BCR-mediated up-regulation of CD80 and CD86 may be enhanced by hCR2 cross-linking, but only under conditions of very low BCR ligand occupancy (38) . As we had failed to detect any additive effect of mCR2 cross-linking to the BCR (Figs 2-4 ) with regard to CD80/86 expression levels with standard saturating levels of anti-BCR mAb (3.4 lg ml ÿ1 ), we next decided to examine CD86 levels after cross-linking the anti-mCR2 mAb, 7E9, to limiting doses of anti-BCR mAb. ) was added to the wells containing mAbs to cross-link the ligated receptors. Cells were then incubated for 17 h in the presence of 10 ng ml ÿ1 IL-4 before the levels of CD80 and CD86 were analyzed. untreated cells (hatched). This is also seen in the presence of anti-CR2 mAbs (filled bars). While there appears to be an effect on CD86 expression after cross-linking mCR2 to the anti-BCR mAb at the lowest level (0.03 lg ml ÿ1 ) of anti-BCR treatment, this increase is still significantly lower than the levels achieved with saturating BCR ligation and, more importantly, is very similar to the levels seen in untreated cells. Thus, crosslinking mCR2 to limiting numbers of BCR molecules, even in the absence of IL-4, also fails to induce CD86 expression.
Discussion
Previously, in vitro studies from our laboratory (25) , as well as those from others (18, 33, 34) , have shown that both human and mouse CR2, expressed on B cells, are capable of mediating efficient antigen presentation for CD4 + T cell recognition. Our findings, that distinct sequences within the cytoplasmic domain of mCR2 are essential for this, as well as for enhancing BCR-mediated presentation (25) , raise the possibility that CR2-mediated antigen presentation may occur in vivo. Unlike BCR-mediated antigen presentation, however, hCR2-mediated antigen presentation leads to insufficient T cell stimulation for subsequent B cell differentiation and antibody secretion (35) . Thornton et al. (33) using human B cells, we find no evidence of CR2-induced co-stimulatory molecule expression. In the study of Kozono et al., mCR2 was ligated using anti-CR2 mAbs followed by cross-linking with intact anti-rat secondary antibodies. While these secondary reagents were shown to lack anti-BCR cross-reactivity, cross-linking to the B cell FcRcII was not excluded (36) . Indeed, in the study of Thornton et al. (33) , when CR2 was cross-linked to FcRcII, CD80 levels were seen to be elevated. In our present study, the anti-CR2 monoclonals were checked prior to use and shown to be negative for FcRcII binding. The cross-linking in our study was achieved using streptavidin rather than secondary antibodies, so removing any possible FcR engagement. More importantly, we have also generated identical results, after ligating mCR2 on B cells purified from mice lacking expression of FcRcII. Somewhat surprisingly, however, when we specifically crosslinked mCR2 to FcRcII on B cells using the 2.4G2 mAb, no increased levels of CD80 or CD86 were seen. It may be that while the binding of the 2.4G2 mAb by FcRcII does block subsequent antibody, its binding does not replicate the binding seen with Fc regions of intact antibodies as were used by Kozono et al. (36) . Alternately, the results from the study of Kozono et al. may be due to other differences in the experimental systems. However, our present study, in agreement with others previously reported, clearly demonstrates that, while capable of efficient antigen presentation independent of other antigen receptor (e.g. BCR, FcRcII) engagements (18, 25, 33, 34) , mCR2 performs this in the absence of increased co-stimulatory molecule expression.
These findings demand an explanation for the role of CR2-mediated antigen presentation by B cells. In the absence of any co-stimulation expressed by APC, responding T cells are stimulated sub-optimally and may develop into an 'anergic' ) was added to the wells containing mAbs to cross-link the ligated receptors. Cells were incubated for 17 h either in the presence (A) or in the absence (B) of 10 ng ml ÿ1 IL-4 before the levels of CD86 were analyzed and the MFIs plotted.
phenotype. This can lead to either permanent or transient unresponsiveness, cell death or the development of regulatory function [reviewed in (13) ]. Thus, only the very limited number of B cell clones capable of capturing and presenting antigen via specific BCR expression supply the correct co-stimulatory signals to responding CD4 + T cells. So what is the role of CR2-mediated antigen presentation leading to sub-optimal signal delivery? Clearly, one advantage is that the numbers of B cells that can act as non-specific APC are vast, compared with those expressing an antigen-'specific' BCR. Maybe, by accumulating large numbers of sub-optimal co-stimulatory signals, received from B cells presenting antigen via CR2, T cells may use this abundant population as APC. Clearly though, this sub-optimal signal is not sufficient to induce cognate B cell help, and indeed, irrelevant antibody secretion does not occur. It may, however, result in an increase in antigen-specific CD4 + T cells providing non-cognate or 'bystander help' to enhance the cognate 'help' received by antigen-specific B cells. Additional studies will have to be performed to test this hypothesis.
